Suicidal ideation during antidepressant treatment: Do genetic predictors exist?

CNS Drugs

Volumn 25, Issue 6, 2011, Pages 459-471

  Perroud, Nader ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antidepressants; Pharmacogenetics; Pharmacogenomics; Suicide

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FK 506 BINDING PROTEIN; GLUTAMATE RECEPTOR; INTERLEUKIN 28; INTERLEUKIN RECEPTOR; KAINIC ACID; NORTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; VENLAFAXINE;

ARTICLE; BECK DEPRESSION INVENTORY; BEHAVIOR THERAPY; BRAIN FUNCTION; COGNITIVE THERAPY; DEPRESSION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NORADRENERGIC SYSTEM; PHARMACOGENOMICS; PHENOTYPE; PHYSICIAN; PRIORITY JOURNAL; RATING SCALE; SUICIDAL IDEATION; SUICIDE ATTEMPT;

ANTIDEPRESSIVE AGENTS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SUICIDAL IDEATION;

EID: 79958137948     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11589420-000000000-00000     Document Type: Article

References (87)

1. Hammad TA, Laughren T, Racoosin J. Suicidality in pe- diatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63 (3): 332-9. (Pubitemid 43345358)
2. US Food and Drug Administration. Clinical review: re- lationship between antidepressant drugs and suicidality in adults [online]. Available from URL: http://www.fda.gov/ [Accessed 2008 Apr 28].
3. US Food and Drug Administration. Antidepressant use in children, adolescents and adults: medication guide for antidepressant drugs [online]. Available from URL: http:// www.fda.gov/CDER/Drug/antidepressants/default.htm [Accessed 2008 Apr 28].
4. Medicines and Healthcare products Regulatory Agency. Safety of selective serotonin reuptake inhibitor antide-pressants, 2004 [online]. Available from URL: http://www.mhra.gov.uk/index.htm [Accessed 2010 Dec 13].
5. Friedman RA, Leon AC. Expanding the black box: depres- sion, antidepressants, and the risk of suicide. N Engl J Med 2007; 356 (23): 2343-6. (Pubitemid 46883767)
6. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164 (9): 1356-63. (Pubitemid 47461135)
7. Healy D, Whitaker C. Antidepressants and suicide: risk-benefit conundrums. J Psychiatry Neurosci 2003; 28 (5): 331-7. (Pubitemid 37211275)
8. Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psycho-som 2003; 72 (2): 71-9. (Pubitemid 36302475)
9. Machado-Vieira R, Salvadore G, Luckenbaugh DA, et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 2008; 69 (6): 946-58. (Pubitemid 351944948)
10. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292 (3): 338-43. (Pubitemid 38944257)
11. Nutt DJ. Death and dependence: current controversies over the selective serotonin reuptake inhibitors. J Psycho-pharmacol 2003; 17 (4): 355-64. (Pubitemid 38076329)
12. Perlis RH, Beasley Jr CM, Wines Jr JD, et al. Treatment- associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom 2007; 76 (1): 40-6. (Pubitemid 46005718)
13. Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf 1993; 8 (3): 186-212. (Pubitemid 23123065)
14. Akiskal HS, Benazzi F, Perugi G, et al. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord 2005; 85 (3): 245-58. (Pubitemid 40386508)
15. Berk M, Dodd S. Are treatment emergent suicidality and decreased response to antidepressants in younger patients due to bipolar disorder being misdiagnosed as unipolar depression? Med Hypotheses 2005; 65 (1): 39-43. (Pubitemid 40704527)
16. Harada T, Sakamoto K, Ishigooka J. Incidence and pre- dictors of activation syndrome induced by antidepressants. Depress Anxiety 2008; 25 (12): 1014-9.
17. Culpepper L, Davidson JR, Dietrich AJ, et al. Suicidality as a possible side effect of antidepressant treatment. J Clin Psychiatry 2004; 65 (6): 742-9.
18. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 1998; 12 (2): 192-214. (Pubitemid 28312578)
19. Benazzi F. Suicidal ideation and depressive mixed states. Psychother Psychosom 2005; 74 (1): 61-2. (Pubitemid 40091421)
20. Baldassano CF, Truman CJ, Nierenberg A, et al. Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry 1996; 37 (2): 122-4. (Pubitemid 26077588)
21. Perroud N, Uher R, Marusic A, et al. Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. BMC Med 2009; 7: 60.
22. Balazs J, Benazzi F, Rihmer Z, et al. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord 2006; 91 (2-3): 133-8.
23. Pokorny AD. Prediction of suicide in psychiatric patients: report of a prospective study. Arch Gen Psychiatry 1983; 40 (3): 249-57. (Pubitemid 13161595)
24. Goldstein RB, Black DW, Nasrallah A, et al. The prediction of suicide: sensitivity, specificity, and predictive value of a multivariate model applied to suicide among 1906 patients with affective disorders. Arch Gen Psychiatry 1991; 48 (5): 418-22.
25. van Egmond M, Diekstra RF. The predictability of suicidal behavior: the results of a meta-analysis of published studies. Crisis 1990; 11 (2): 57-84.
26. Anderson RN. Deaths: leading causes for 1999. Natl Vital Stat Rep 2001; 49 (11): 1-87.
27. Brent DA, Mann JJ. Family genetic studies, suicide, and suicidal behavior. Am J Med Genet C Semin Med Genet 2005; 133C (1): 13-24. (Pubitemid 40194125)
28. Fu Q, Heath AC, Bucholz KK, et al. A twin study of genetic and environmental influences on suicidality in men. Psy-chol Med 2002; 32 (1): 11-24. (Pubitemid 33150500)
29. Butler AW, Breen G, Tozzi F, et al. A genomewide linkage study on suicidality in major depressive disorder confirms evidence for linkage to 2p12. Am J Med Genet B Neu-ropsychiatr Genet 2010; 153B (8): 1465-73.
30. 0-UTR of the NOS1 gene was associated with completed suicides in Japanese male population. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34 (6): 992-6.
31. Wang Y, Zhang J, Liu B, et al. Genetic polymorphisms in the SCN8A gene are associated with suicidal behavior in psychiatric disorders in the Chinese population. World J Biol Psychiatry 2010; 11 (8): 956-63.
32. Nedic G, Nikolac M, Sviglin KN, et al. Association study of a functional catechol-O-methyltransferase (COMT) Val108/158Met polymorphism and suicide attempts in patients with alcohol dependence. Int J Neuropsychopharmacol 2011; 14 (3): 377-88.
33. Zalsman G, Patya M, Frisch A, et al. Association of poly- morphisms of the serotonergic pathways with clinical traits of impulsive-aggression and suicidality in adolescents: a multi-center study. World J Biol Psychiatry 2011; 12 (1): 33-41.
34. Uher R, Perroud N. Probing the genome to understand suicide. Am J Psychiatry 2010; 167: 1425-7.
35. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treat- ment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004; 25 (1): 119-42. (Pubitemid 38230109)
36. Uher R, Farmer A, Maier W, et al. Measuring depression: comparison and integration of three scales inthe GENDEP study. Psychol Med 2008; 38 (2): 289-300. (Pubitemid 351156595)
37. Hennings JM, Owashi T, Binder EB, et al. Clinical char- acteristics and treatment outcome in a representative sample of depressed inpatients: findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009; 43 (3): 215-29.
38. Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299 (8): 901-13. (Pubitemid 351397065)
39. Brent D, Melhem N, Turecki G. Pharmacogenomics of sui- cidal events. Pharmacogenomics 2010; 11 (6): 793-807.
40. Perlis RH, Purcell S, Fava M, et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007; 64 (6): 689-97. (Pubitemid 46878669)
41. Laje G, Allen AS, Akula N, et al. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet Genomics 2009; 19 (9): 666-74.
42. Laje G, Paddock S, Manji H, et al. Genetic markers of sui- cidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007; 164 (10): 1530-8. (Pubitemid 350069732)
43. Perroud N, Aitchison KJ, Uher R, et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharma-cology 2009; 34 (12): 2517-28.
44. Menke A, Lucae S, Kloiber S, et al. Genetic markers within glutamate receptors associated with antidepressant treatment-emergent suicidal ideation. Am J Psychiatry 2008; 165 (7): 917-8. (Pubitemid 351948730)
45. Brent D, Melhem N, Ferrell R, et al. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry 2010; 167 (2): 190-7.
46. Zisook S, Trivedi MH, Warden D, et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalo-pram in the STAR*D study. J Affect Disord 2009; 117 (1-2): 63-73.
47. Perroud N, Uher R, Ng M, et al. Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics J. Epub 2010 Sep 28.
48. Dwivedi Y, Rao JS, Rizavi HS, et al. Abnormal expression and functional characteristics of cyclic adenosine mono-phosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60 (3): 273-82. (Pubitemid 36307438)
49. Young LT, Bezchlibnyk YB, Chen B, et al. Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: effects of diagnosis, suicide, and drug treatment. Biol Psychiatry 2004; 55 (6): 570-7. (Pubitemid 38315030)
50. Baud P, Courtet P, Perroud N, et al. Catechol-O-methyl- transferase polymorphism (COMT) in suicide attempters: a possible gender effect on anger traits. Am J Med Genet B Neuropsychiatr Genet 2007; 144B (8): 1042-7. (Pubitemid 350207779)
51. Perlis RH, Purcell S, Fagerness J, et al. Clinical and genetic dissection of anger expression and CREB1 polymorphisms in major depressive disorder. Biol Psychiatry 2007; 62 (5): 536-40. (Pubitemid 47284030)
52. Palucha A, Pilc A. The involvement of glutamate in the pa- thophysiology of depression. Drug News Perspect 2005; 18 (4): 262-8.
53. Dwivedi Y, Rizavi HS, Conley RR, et al. Altered gene ex- pression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60 (8): 804-15. (Pubitemid 36960912)
54. Altar CA, Whitehead RE, Chen R, et al. Effects of electro- convulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003; 54 (7): 703-9. (Pubitemid 37281386)
55. Coppell AL, Pei Q, Zetterstrom TS. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 2003; 44 (7): 903-10. (Pubitemid 36515026)
56. Escriba PV, Ozaita A, Garcia-Sevilla JA. Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology 2004; 29 (8): 1512-21. (Pubitemid 38982244)
57. Wakeno M, Kato M, Okugawa G, et al. The alpha 2A- adrenergic receptor gene polymorphism modifies antide-pressant responses to milnacipran. J Clin Psychopharmacol 2008; 28 (5): 518-24.
58. Oquendo MA, Mann JJ. The biology of impulsivity and suicidality. Psychiatr Clin North Am 2000; 23 (1): 11-25. (Pubitemid 30140469)
59. Ising M, Depping AM, Siebertz A, et al. Polymorphisms in the FKBP5 gene region modulate recovery from psycho-social stress in healthy controls. Eur J Neurosci 2008; 28 (2): 389-98.
60. Binder EB, Salyakina D, Lichtner P, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004; 36 (12): 1319-25. (Pubitemid 39577942)
61. Perroud N, Bondolfi G, Uher R, et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 2011; 12 (3): 365-77.
62. Mann JJ, Currier D. A review of prospective studies of biologic predictors of suicidal behavior in mood disorders. Arch Suicide Res 2007; 11 (1): 3-16.
63. Scammell JG, Denny WB, Valentine DL, et al. Overexpression of the FK506-binding immunophilin FKBP51 is the common cause of glucocorticoid resistance in three New World primates. Gen Comp Endocrinol 2001; 124 (2): 152-65. (Pubitemid 33065587)
64. Roy A, Gorodetsky E, Yuan Q, et al. Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology 2010; 35 (8): 1674-83.
65. Janssen HL, Brouwer JT, van der Mast RC, et al. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21 (2): 241-3. (Pubitemid 24270552)
66. Akum BF, Chen M, Gunderson SI, et al. Cypin regulates dendrite patterning in hippocampal neurons by promoting microtubule assembly. Nat Neurosci 2004; 7 (2): 145-52. (Pubitemid 38129790)
67. Feyissa AM, Chandran A, Stockmeier CA, et al. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33 (1): 70-5.
68. Guipponi M, Deutsch S, Kohler K, et al. Genetic and epi- genetic analysis of SSAT gene dysregulation in suicidal behavior. Am J Med Genet B Neuropsychiatr Genet 2009; 150B (6): 799-807.
69. Brown G. A review of suicide assessment measures for in- tervention research with adults and older adults. Philadelphia (PA): University of Pennsylvania, 2002.
70. Nock MK, Wedig MM, Janis IB, et al. Self-injurious thoughts and behaviors. In: Hunsley J, Mash EJ, editors. A guide to assessments that work. London: Oxford University Press, 2008: 158-78.
71. Range LM, Knott EC. Twenty suicide assessment instru- ments: evaluation and recommendations. Death Stud 1997; 21 (1): 25-58. (Pubitemid 27056151)
72. Winters NC, Myers K, Proud L. Ten-year review of rating scales: III. Scales assessing suicidality, cognitive style, and self-esteem. J Am Acad Child Adolesc Psychiatry 2002; 41 (10): 1150-81. (Pubitemid 38338036)
73. Newport DJ, Levey LC, Pennell PB, et al. Suicidal ideation in pregnancy: assessment and clinical implications. Arch Womens Ment Health 2007; 10 (5): 181-7. (Pubitemid 47493623)
74. Kessler RC, Berglund P, Borges G, et al. Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003. JAMA 2005; 293 (20): 2487-95. (Pubitemid 40705730)
75. Suicidal behavior and psychotropic medication: accepted as a consensus statement by the ACNP Council, March 2, 1992. Neuropsychopharmacology 1993; 8 (2): 177-83.
76. Meyer RE, Salzman C, Youngstrom EA, et al. Suicidality and risk of suicide: definition, drug safety concerns, and a necessary target for drug development. A consensus statement. J Clin Psychiatry 2010; 71 (8): e1-21.
77. Meyer RE, Salzman C, Youngstrom EA, et al. Suicidality and risk of suicide: definition, drug safety concerns, and a necessary target for drug development. A brief report. J Clin Psychiatry 2010; 71 (8): 1040-6.
78. Price AL, Kryukov GV, de Bakker PI, et al. Pooled asso- ciation tests for rare variants in exon-resequencing studies. Am J Hum Genet 2010; 86 (6): 832-8.
79. Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet 2001; 69 (1): 124-37. (Pubitemid 32614025)
80. Frazer KA, Murray SS, Schork NJ, et al. Human genetic variation and its contribution to complex traits. Nat Rev Genet 2009; 10 (4): 241-51.
81. Iyengar SK, Elston RC. The genetic basis of complex traits: rare variants or "common gene, common disease"? Methods Mol Biol 2007; 376: 71-84. (Pubitemid 350189861)
82. Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet 2008; 83 (3): 311-21.
83. Smith DJ, Lusis AJ. The allelic structure of common disease. Hum Mol Genet 2002; 11 (20): 2455-61. (Pubitemid 35174709)
84. Caspi A, Hariri AR, Holmes A, et al. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 2010; 167 (5): 509-27.
85. Nemeroff CB, Heim CM, Thase ME, et al. Differential re- sponses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 2003; 100 (24): 14293-6. (Pubitemid 37499230)
86. Hashimoto K. Brain-derived neurotrophic factor as a bio- marker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010; 64 (4): 341-57.
87. Karege F, Vaudan G, Schwald M, et al. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 2005; 136 (1-2): 29-37 (Pubitemid 40704606)